Grifols SA
GRFS10.860USD
+0.080+0.74%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
7.39BCap. mercado
43.58P/E TTM
Más Datos de Grifols SA Compañía
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Información de la empresa
Símbolo de cotizaciónGRFS
Nombre de la empresaGrifols SA
Fecha de salida a bolsaMay 17, 2006
Director ejecutivoMr. Jose Ignacio (Nacho) Abia
Número de empleados23833
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 17
DirecciónParque Empresarial Can Sant Joan
CiudadSANT CUGAT DEL VALLES
Bolsa de valoresNASDAQ Global Select Consolidated
PaísSpain
Código postal08174
Teléfono34935710000
Sitio Webhttps://www.grifols.com/
Símbolo de cotizaciónGRFS
Fecha de salida a bolsaMay 17, 2006
Director ejecutivoMr. Jose Ignacio (Nacho) Abia
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Laura De La Cruz Galan
Ms. Laura De La Cruz Galan
Non-Member Assistant Secretary of the Board
Non-Member Assistant Secretary of the Board
--
--
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Secretary of the Board of Directors
Non-Member Secretary of the Board of Directors
--
--
Mr. Joerg Schuettrumpf
Mr. Joerg Schuettrumpf
Chief Scientific Innovation Officer
Chief Scientific Innovation Officer
--
--
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Proprietary Director
Proprietary Director
--
--
Mr. Daniel Fleta Coit
Mr. Daniel Fleta Coit
Chief Industrial Services Officer
Chief Industrial Services Officer
--
--
Mr. Victor Grifols Deu
Mr. Victor Grifols Deu
Proprietary Director
Proprietary Director
--
--
Ms. Montserrat Munoz Abellana
Ms. Montserrat Munoz Abellana
Independent Director
Independent Director
--
--
Mr. Inigo Sanchez-Asiain Mardones
Mr. Inigo Sanchez-Asiain Mardones
Independent Director
Independent Director
--
--
Ms. Susana Gonzalez Rodriguez
Ms. Susana Gonzalez Rodriguez
Independent Director
Independent Director
--
--
Mr. Jordi Balsells Valls
Mr. Jordi Balsells Valls
President - Plasma Procurement
President - Plasma Procurement
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Laura De La Cruz Galan
Ms. Laura De La Cruz Galan
Non-Member Assistant Secretary of the Board
Non-Member Assistant Secretary of the Board
--
--
Ms. Nuria Martin Barnes
Ms. Nuria Martin Barnes
Non-Member Secretary of the Board of Directors
Non-Member Secretary of the Board of Directors
--
--
Mr. Joerg Schuettrumpf
Mr. Joerg Schuettrumpf
Chief Scientific Innovation Officer
Chief Scientific Innovation Officer
--
--
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Proprietary Director
Proprietary Director
--
--
Mr. Daniel Fleta Coit
Mr. Daniel Fleta Coit
Chief Industrial Services Officer
Chief Industrial Services Officer
--
--
Mr. Victor Grifols Deu
Mr. Victor Grifols Deu
Proprietary Director
Proprietary Director
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q2
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States/Canada
4.42B
56.67%
Rest of the World
1.71B
21.96%
European Union
1.21B
15.50%
Spain
457.59M
5.87%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Brandes Investment Partners, L.P.
9.97%
Capital World Investors
8.33%
Permian Investment Partners, LP
7.00%
Black Creek Investment Management, Inc.
4.91%
Armistice Capital LLC
3.59%
Other
66.19%
Accionistas
Accionistas
Proporción
Brandes Investment Partners, L.P.
9.97%
Capital World Investors
8.33%
Permian Investment Partners, LP
7.00%
Black Creek Investment Management, Inc.
4.91%
Armistice Capital LLC
3.59%
Other
66.19%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
27.38%
Hedge Fund
18.23%
Investment Advisor/Hedge Fund
6.83%
Research Firm
4.06%
Pension Fund
1.13%
Sovereign Wealth Fund
0.75%
Bank and Trust
0.14%
Family Office
0.03%
Other
41.44%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
304
150.62M
58.33%
-8.38M
2025Q1
318
151.56M
58.69%
-8.09M
2024Q4
317
145.36M
56.29%
-25.01M
2024Q3
302
144.07M
55.96%
-19.66M
2024Q2
298
148.36M
57.63%
-6.71M
2024Q1
295
140.29M
54.61%
+6.03M
2023Q4
303
126.55M
49.26%
-7.36M
2023Q3
316
123.59M
48.19%
-7.60M
2023Q2
331
119.70M
46.67%
-25.54M
2023Q1
347
120.97M
47.21%
-11.90M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Brandes Investment Partners, L.P.
25.74M
9.97%
+5.25M
+25.59%
Mar 31, 2025
Capital World Investors
21.52M
8.33%
+388.01K
+1.84%
Mar 31, 2025
Permian Investment Partners, LP
18.08M
7%
+1.89M
+11.70%
Mar 31, 2025
Black Creek Investment Management, Inc.
12.69M
4.91%
+1.44M
+12.79%
Mar 31, 2025
Armistice Capital LLC
9.28M
3.59%
-758.00K
-7.55%
Mar 31, 2025
Millennium Management LLC
8.57M
3.32%
-783.49K
-8.38%
Mar 31, 2025
Soleus Capital Management, L.P.
7.09M
2.75%
+484.40K
+7.33%
Mar 31, 2025
Goldman Sachs & Company, Inc.
3.66M
1.42%
+275.63K
+8.15%
Mar 31, 2025
Harris Associates L.P.
3.44M
1.33%
-284.90K
-7.65%
Mar 31, 2025
Janus Henderson Investors
3.05M
1.18%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Brandes US Small-Mid Cap Value ETF
1.82%
Brandes International ETF
1.72%
Capital Group International Core Equity ETF
0.23%
iShares Biotechnology ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
SPDR S&P Kensho New Economies Composite ETF
0.04%
ActivePassive International Equity ETF
0.03%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Ver más
Brandes US Small-Mid Cap Value ETF
Proporción1.82%
Brandes International ETF
Proporción1.72%
Capital Group International Core Equity ETF
Proporción0.23%
iShares Biotechnology ETF
Proporción0.15%
ProShares Ultra Nasdaq Biotechnology
Proporción0.12%
Invesco Nasdaq Biotechnology ETF
Proporción0.12%
SPDR S&P Kensho New Economies Composite ETF
Proporción0.04%
ActivePassive International Equity ETF
Proporción0.03%
SPDR Portfolio Developed World ex-US ETF
Proporción0.01%
Fidelity Nasdaq Composite Index ETF
Proporción0.01%
Dividendos
Un total de
436.88M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
May 25, 2021
GRFS.NB Interim Cash Dividend of gross USD 0.456586 paid on Jun 14, 2021 going ex on Jun 03, 2021
Jun 04, 2021
Jun 14, 2021
Jun 03, 2021
Oct 23, 2020
GRFS.NB Interim Cash Dividend of gross USD 0.201439 paid on Nov 09, 2020 going ex on Oct 30, 2020
Nov 02, 2020
Nov 09, 2020
Oct 30, 2020
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
